Biolase Operating Income 2010-2024 | BIOL

Biolase operating income from 2010 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Biolase Annual Operating Income
(Millions of US $)
2023 $-18
2022 $-25
2021 $-16
2020 $-19
2019 $-16
2018 $-21
2017 $-18
2016 $-15
2015 $-20
2014 $-18
2013 $-11
2012 $-3
2011 $-4
2010 $-11
2009 $-3
Biolase Quarterly Operating Income
(Millions of US $)
2024-03-31 $-5
2023-12-31 $-5
2023-09-30 $-4
2023-06-30 $-4
2023-03-31 $-5
2022-12-31 $-8
2022-09-30 $-8
2022-06-30 $-5
2022-03-31 $-4
2021-12-31 $-4
2021-09-30 $-3
2021-06-30 $-3
2021-03-31 $-6
2020-12-31 $-6
2020-09-30 $-4
2020-06-30 $-4
2020-03-31 $-5
2019-12-31 $-3
2019-09-30 $-5
2019-06-30 $-3
2019-03-31 $-4
2018-12-31 $-7
2018-09-30 $-5
2018-06-30 $-5
2018-03-31 $-5
2017-12-31 $-5
2017-09-30 $-5
2017-06-30 $-4
2017-03-31 $-4
2016-12-31 $-4
2016-09-30 $-3
2016-06-30 $-3
2016-03-31 $-4
2015-12-31 $-2
2015-09-30 $-5
2015-06-30 $-7
2015-03-31 $-5
2014-12-31 $-4
2014-09-30 $-3
2014-06-30 $-6
2014-03-31 $-5
2013-12-31 $-2
2013-09-30 $-4
2013-06-30 $-2
2013-03-31 $-3
2012-12-31 $1
2012-09-30 $-0
2012-06-30 $-2
2012-03-31 $-2
2011-12-31 $-2
2011-09-30 $-1
2011-06-30 $-1
2011-03-31 $-0
2010-12-31 $0
2010-09-30 $-2
2010-06-30 $-4
2010-03-31 $-5
2009-12-31 $-1
2009-09-30 $1
2009-06-30 $2
2009-03-31 $-5
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $0.005B $0.049B
Biolaw Technology, Inc. is the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.
Stock Name Country Market Cap PE Ratio
McKesson (MCK) United States $76.685B 21.51
Becton Dickinson (BDX) United States $67.549B 19.11
Cardinal Health (CAH) United States $24.405B 13.95
West Pharmaceutical Services (WST) United States $24.275B 43.51
Align Technology (ALGN) United States $19.273B 37.21
Cooper (COO) United States $18.612B 27.45
Labcorp (LH) United States $16.850B 14.51
Henry Schein (HSIC) United States $8.426B 14.99
DENTSPLY SIRONA (XRAY) United States $5.421B 14.04
Merit Medical Systems (MMSI) United States $4.753B 26.05
CONMED (CNMD) United States $2.190B 19.86
Patterson (PDCO) United States $2.027B 9.71
STAAR Surgical (STAA) United States $2.025B 77.77
Atrion (ATRI) United States $0.794B 42.40
Lifevantage (LFVN) United States $0.088B 11.31
Pro-Dex (PDEX) United States $0.066B 33.31